Abstract
INTRODUCTION
According to the Scientific Registry of Transplant Reci pients database, since 2005 over 6000 liver transplants have been performed on an annual basis. Hepatitis C virus (HCV) has consistently been the most common indica tion for liver transplantation and challenging due to the possibility of viral recurrence posttransplant. Recurrent HCV had been a major problem for patients post liver transplantation, but with the new direct acting antiviral (DAA) therapies, this problem is steadily declining. Even with resolution of this challenge, identifying factors that may accelerate graft loss or damage is still essential.
Originally established for mortality post transjugular intrahepatic portosystemic shunts, the laboratory based Model for End Stage Liver Disease (MELD and MELD Na) is now the primary measure for liver organ allocation in the United States [1] . Since the use of MELD began in 2002, wait list mortality has significantly decreased as patients are prioritized effectively, however patients on the wait list still suffer from complications of end stage liver disease and portal hypertension such as gastrointestinal bleeding, encephalopathy, ascites, renal failure, and infection [2] . Liver disease patients, with decreased levels of com plement proteins and decreased opsonization, live in a relatively immunocompromised state and are at high risk of developing bacterial, viral, or fungal infections [3] . Ascites reportedly occurs in 7% to 23% of hospitalized end stage liver disease patients [4] . An initial episode of spontaneous bacterial peritonitis (SBP) occurs in about 10% of these patients [5] . Infection related to SBP can have severe ramifications in the development of renal failure and mortality of patients while on the transplant wait list.
The utility of MELD in organ allocation is well esta blished, but its extrapolation to posttransplant survival or graft outcomes is still unclear. Further, in the post MELD era, limited studies have investigated the role of SBP on posttransplant outcomes [6] . Therefore, in order to understand the role of infections on posttransplant outcomes, we aimed to investigate the incidence of SBP in pretransplant patients and its effect on post transplant mortality and graft failure in the era prior to DAA therapy.
MATERIALS AND METHODS
We investigated the United States organ procurement and transplant network (OPTN) dataset for liver trans plants from February 2002 until November 2009 for liver graft recipients with a reported history of pre transplant SBP. All patients who eventually underwent liver transplantation were included in the analysis. If the patient did not have a history of SBP or if the question was left blank (or "unknown" was selected) on the Adult Liver Transplant Recipient Registration Worksheet submitted to the United Network for Organ Sharing, the recipient was assumed to not have pre transplant SBP. The population with a history of SBP was compared to those without the history of SBP for multiple pre and posttransplant characteristics. Recipient etiology of disease was categorized as HCV, hepatitis B, nonalcoholic steatohepatitis or cryptogenic, alcohol alone, cholestatic liver disease, autoimmune, liver malignancy, or other. Etiologies of graft failure included biliary, de novo autoimmune hepatitis, recurrent (nonviral) disease, infection, primary nonfunction, recurrent viral hepatitis, acute rejection, chronic rejection, and vascular thrombosis. Laboratory (nonexception) MELD scores were used for all recipients.
Demographics, recipient, donor, and surgical chara cteristics were compared between groups using the χ 2 test for categorical variables and the Student ttest for continuous variables. Univariate posttransplant sur vival models were constructed using the KaplanMeier technique and multivariate models were constructed using the Cox proportional hazards model. Variables known to influence post-transplant survival from previous studies or those variables found to be significant in the univariate analysis to a level of less than 0.20 were included in multivariate models using a whole model (nonstepwise) analysis. Because of the finding of a relationship between SBP and graft failure due to recurrent HCV, a multivariate logistic regression model was developed to determine those variables independently predictive of recurrent HCV. No data imputation was used. All statistical testing was two sided and the level of type one error deemed to be statistically significant was assumed to be less than or equal to 0.05. All dataset manipulation and analysis was performed using SAS (version 9.2, Cary, NC, United States). Local institutional review board approval was not required for analysis of this de-identified dataset.
RESULTS
The OPTN data set contained information on 47880 patients transplanted during the study period. The chara ctersitics of the study population are outlined in Table 1 . Of this population, 1966 (4.11%) patients were reported to have a history of pretransplant SBP. Patients with a history of SBP tended to be older (50.5 mean years in the SBP population vs 48.0 in the nonSBP population, P < 0.0001), male (72.7% vs 65.2%, P < 0.0001), and have a higher MELD score at the time of liver transplantation (25.3 vs 20.3, P < 0.0001). The etiology of liver disease was sigificantly different between those recipients who had pretransplant SBP compared to those that did not. HCV was signficantly more prevelant in the SBP population (41.1% vs 29.5%, P < 0.0001). Table 2 shows the distribution and causes of graft failure in the posttransplant time period. While overall graft loss was uncommon, compared to those without a history of SBP, patients that had pretransplant SBP had higher rates of graft loss from recurrent HCV (3.6% vs 2.0%, P < 0.0001), infections leading to graft loss (1.9% vs 1.3%, P = 0.02), primary nonfunction (4.3% vs 3.0%, P < 0.0001) and chronic rejection (1.1% vs 0.7%, P = 0.04). In regards to allcause survival, patients having pretransplant SBP had worse unadjusted one year post transplant survival (82.8% vs 86.5%, P < 0.0001) and this difference widened at two years (76.5% vs 81.6%, P < 0.0001). Figure 1 shows the KaplanMeier survival analysis. There was a statistically significant difference in allcause survival in patients with a history of SBP vs those without (P < 0.0001).
In order to account for multiple factors influencing graft loss in this population, we developed a multivariable logistic regression model including factors known to affect survival rates: Age of recipient, age of donor, MELD score, history of previous transplant, and history of HCV. Table 3 shows the results of this analysis. A pretransplant history of SBP was found to be an independent risk factor for posttransplant graft failure imparting a 57% increased risk of graft failure (OR = 1.57, 95%CI: 1.222.02, P < 0.001). Table 4 shows the results of a mutivariate pro prortional hazards survival model predicting death due to recurrent HCV. Once again, a pretransplant history of SBP was independently predictive of mortality due to recurrent HCV (HR = 1.11, 95%CI: 1.021.21, P < 0.017) after liver transplantation.
DISCUSSION
We have shown that HCV patients prior to the advent of DAA agents had a higher incidence of pretransplant SBP than other patients on the liver transplant wait list. Further, SBP history resulted in a higher rate of graft loss due to recurrent HCV infection and chronic rejection. This group also had an 11.2% greater risk of posttransplant mortality. In a multivariate Cox regression model, SBP was found to be an independent risk factor for post transplant mortality.
Patients with a diagnosis of active HCV infection at the time of transplant have a known predisposition to graft failure due to HCV recurrence. However, the rate of progression to cirrhosis and graft failure is unpredictable. Certain known risk factors such as the donor's age, post transplant CMV infection, HIV coinfection, the use of T cell depleting therapies, pulsed steroids, and other donor risk factors have all been associated with poorer outcomes [7] . SBP has not been studied in this regard. Our results show that a history of pretransplant SBP may contribute to worse survival and an increased risk of graft failure. As our study shows, 40% of pretransplant SBP patients in this cohort suffered from HCV, whereas only 30% of a control, nonSBP pretransplant group suffered from HCV. Prior treatment regimens, which included interferon, to decrease HCV levels in pretransplant candidates possessed their own risks and had shown an increase the rate of bacterial infections in these patients [8] . The rate of infection, especially the incidence of SBP in pati ents not receiving prophylaxis therapy, in Child Pugh B/C patients was higher than matched controls [8] . Several etiologies had been proposed, including the neutropenic and granulotoxic effect of interferon causing an increase susceptibility to bacterial infections. These studies show an increased risk of infection, including SBP, in HCV patients with poor liver function. With our data showing the deleterious effect of SBP on transplant outcomes, it supports the careful choice of HCV patients that were selected in the past to undergo interferon based therapies pretransplant and the importance of SBP prophylaxis in this group with proper indications [8, 9] . Limited studies from the preMELD era did not show that pre-transplant SBP influenced post-transplant outcomes. A study following 100 patients, showed that 32% of patients developed a pretransplant infection. The infections ranged from SBP (35.6%), blood stream infections (28.9%), cellulitis (13.3%), pneumonia (8.9%), urinary tract infections (6.7%), and other infections (6.7%) [10] . After following this group, the study found that patients with pretransplant infections were less likely to be transplanted from home and required longer hospital stays, but the mortality at 90 and 180 d posttransplant did not differ significantly compared to individuals without pretransplant infections. As shown by our Kaplan Meier survival curves in Figure 1 , the survival of the two groups from our analysis of the OPTN database seems to be similar, but then diverges significantly starting at day 250. Therefore, even though the previously mentioned study did not find differences in survival, we feel that with longer followup this difference could have been stati stically significant.
Another single center study, reported that patients with a history of SBP had more severe liver disease as measured by MELD and CTP score, but had similar Table 2 Cause of graft failure in patients with and without a history of spontaneous bacterial peritonitis SBP: Spontaneous bacterial peritonitis.
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History of pre-transplant SBP posttransplant mortality to those without a history of SBP [11] . The patients who developed SBP most commonly suffered from liver disease related to HCV or alcohol. The mean followup time period for this study was 3 years. While mortality or infection rates were not affected, these patients were more likely to require abdominal sur gery 1 year post transplant for hernia repairs, bleeding, and vascular complications [11] . This study reinforces our findings of the large burden of SBP on pretransplant cirrhosis patients and the higher rate of SBP in HCV patients. However, the relatively small sample size and inclusion of patients transplanted in the preMELD era may not be as applicable to the general population. Our cohort studies the transplants occurring after 2002, and includes a multicenter analysis with almost 48000 patient records.
There are several limitations to our study. One of the major limitations is the incomplete reporting of SBP in the OPTN database. We believe it is safe to assume that reported instances of SBP are accurate and have a clear documented episode recognized by the listing health care provider, which prompted this designation. However, the low rates of patients with SBP pretransplant as compared to other studies in the literature, raises the speculation of recall bias from reporting centers on patient's history of SBP. The exact determination of SBP may not be uniform across all centers, and without full accessibility to numbers of SBP episodes, exact cell counts, or ascites fluid analysis we are dependent solely on information from the database. Further, those patients with severe infection due to SBP were likely excluded from transplant listing. Finally, while we may assume that survival statistics and graft loss are accurate in the OPTN database, other posttransplant variables are often incomplete including immunosuppression data and other details regarding HCV recurrence [12] . By using a worst case scenario analysis, if we assume that all patients in the OPTN database without data entered for SBP are included in the control group. Any mortality registered in these patients would only reduce the differences between our groups.
It has been shown that HCV patients being treated with interferon based therapies were at an increased risk of developing SBP [8] . It is unclear if this association is due to the underlying viral hepatitis disease process or related to the treatment regimen that were used. Regardless, stronger surveillance measures and antibiotic prophylaxis pretransplant SBP may be necessary to improve posttransplant outcomes. Also, the new issue as we transition fully to DAA regimens is the decision to treat cirrhosis patients pre vs posttransplant [13, 14] . If patients live in a region with a relatively high average MELD at time of transplant, treating HCV infection pre transplant may put these patients into MELD "purgatory" stable MELD that will not increase transplant priori tization, but continued low quality of life [15] . Due to the low rates of drug interactions between the DAAs and immunosuppression, some patients at higher MELD are deferred for therapy until after transplant. From these results and our experience prior to the advent of DAAs, in those HCV patients we deem necessary to treat post transplant, we should consider prioritizing therapy in those with a history of SBP. Further, we should strive to reduce donor risk factors, minimize pulsed steroids or T cell depleting immunosuppression to prevent post transplant HCV recurrence and graft failure [16, 17] . Over time, we predict the number of transplants performed in the United States stemming from HCV infection to decrease, but the decision to treat these patients around the time of transplant and avoiding SBP will continue to be a challenge.
COMMENTS

Background
This study examines the effect of spontaneous bacterial peritonitis in cirrhosis patients on the wait list for liver transplantation. Using the patients identified in the organ procurement and transplant network (OPTN)/United Network for Organ Sharing (UNOS) database, in the era prior to direct acting antiviral agents, we investigated the effect of spontaneous bacterial peritonitis (SBP) on liver transplant graft loss and posttransplant mortality.
Research frontiers
Future studies focused on the prevention of pretransplant infections, like SBP, and the effect of direct acting antiviral (DAA) therapies on graft loss and mortality is a potential area to study. Further, as the treatment paradigm for pre vs post transplant hepatitis C virus (HCV) therapy changes, it may be worthwhile to examine the change it produces in graft loss from HCV complications.
Innovations and breakthroughs
From our knowledge, this is the first article to assess the effect of SBP on post transplant outcomes from the OPTN dataset. Further it provides a collective experience of our outcomes from the preDAA therapy era which can be used as a basis for future comparison.
Applications
This article has shown the importance of avoiding SBP infections in the pre transplant population. Aggressive prophylaxis and treatment of this infection may have long term implications with regards to graft survival and mortality.
Terminology
SBP: Spontaneous bacterial peritonitis -infection found in the ascites fluid in the peritoneum; DAA: Direct acting antiviral therapies the new class of HCV medications which directly inhibits replication; OPTN/UNOS: The national organization responsible for managing organ allocation, obtaining individual center's data on transplantation, and reporting collective outcomes.
Peer-review
This is a good paper.
